A significant paradigm shift is underway in the treatment of gastrointestinal and metabolic disorders, heralded by the advent of a novel therapeutic class: ileal bile acid transporter (IBAT) inhibitors. This innovative approach targets a fundamental physiological process, offering new hope to patients battling the debilitating symptoms of cholestatic liver diseases. By intervening directly in...